Key result
PROLANIS program maintains normal BP but fails to consistently control BMI and LDL.
Why the study?
Hypertension prevalence in Indonesia is rising partly due to primary care health system weaknesses, prompting the national PROLANIS program whose effectiveness needed evaluation.
Does the PROLANIS program improve blood pressure and comorbidity control in hypertensive patients at primary health care?
Cohort (n=44)
No
Does the PROLANIS program improve blood pressure and comorbidity control in hypertensive patients at primary health care?
The PROLANIS program was effective in maintaining normal blood pressure in hypertensive patients at a primary care center, though its impact on other metabolic comorbidities was inconsistent.
Supports PROLANIS for blood pressure maintenance in primary care hypertension; hypothesis-generating for BMI and LDL control, needing randomized trials.
BACKGROUND: National prevalence of hypertension in Indonesia is increasing in the past few years. One of the reasons is because of the weaknesses in health systems, particularly at the primary care level. To resolve this issue, Indonesian government launched a chronic disease care program (PROLANIS) designed to be done at primary health care with the aim to control hypertension. Wates primary health care routinely conducts the program from April 2018. AIM: This study aims to evaluate the effectivity of PROLANIS in controlling hypertension and its comorbidities at Wates primary health care. METHODS: This study was an observational retrospective cohort study using secondary data from PROLANIS report at Wates primary health care in Mojokerto city, Indonesia. The study population was hypertensive patients that voluntarily joined the program on April 2018 and routinely attend evaluation follow-up every 6 months. Follow-up evaluation including blood pressure (BP), body mass index (BMI), total cholesterol (TC), high-density lipid (HDL), low-density lipid (LDL), triglyceride, and estimated glomerular filtration rate (eGFR). RESULTS: There were 44 participants included for the analysis. Median systolic and diastolic BP were always within normal range. Triglyceride serum level showed an improvement in every follow-up evaluation. BMI and LDL showed an improvement in the first follow-up but deteriorated afterward. TC only showed a remarkable improvement in the last follow-up evaluation, while HDL and eGFR result were fluctuate. CONCLUSION: PROLANIS was effective to control BP at Wates primary health care, but not effective to control all comorbidities. Future study needs to be done to elucidate the effectivity of this program countrywide.
No takes yet. Share an insight, caveat, or question.
Alkaff et al. (2020) conducted a cohort in Hypertension (n=44). PROLANIS (Indonesia Chronic Disease Management Program) was evaluated on Blood pressure and comorbidities (BMI, TC, HDL, LDL, triglyceride, eGFR). The PROLANIS program effectively maintained median blood pressure within normal ranges but did not consistently control comorbidities such as BMI and LDL.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: